NasdaqCM:AQB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$345.9m

Last Updated

2021/08/03 00:36 UTC

Data Sources

Company Financials +

Executive Summary

AquaBounty Technologies, Inc., a biotechnology company, focuses on improving productivity in the commercial aquaculture industry in the United States and Canada. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has AquaBounty Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AQB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: AQB's weekly volatility has decreased from 14% to 8% over the past year.


Market Performance


7 Day Return

0.8%

AQB

0.9%

US Biotechs

-0.4%

US Market


1 Year Return

48.9%

AQB

21.4%

US Biotechs

34.4%

US Market

Return vs Industry: AQB exceeded the US Biotechs industry which returned 24.5% over the past year.

Return vs Market: AQB exceeded the US Market which returned 35.9% over the past year.


Shareholder returns

AQBIndustryMarket
7 Day0.8%0.9%-0.4%
30 Day-11.1%-0.6%-0.4%
90 Day-7.9%5.9%4.0%
1 Year48.9%48.9%23.1%21.4%36.5%34.4%
3 Year81.0%81.0%22.9%16.8%62.0%51.9%
5 Yearn/a43.7%32.4%121.8%97.2%

Long-Term Price Volatility Vs. Market

How volatile is AquaBounty Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AquaBounty Technologies undervalued compared to its fair value and its price relative to the market?

1.49x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AQB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AQB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AQB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AQB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AQB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AQB is good value based on its PB Ratio (1.5x) compared to the US Biotechs industry average (2.8x).


Future Growth

How is AquaBounty Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-15.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AQB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AQB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AQB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AQB's revenue (60.6% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: AQB's revenue (60.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AQB is forecast to be unprofitable in 3 years.


Past Performance

How has AquaBounty Technologies performed over the past 5 years?

-16.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AQB is currently unprofitable.

Growing Profit Margin: AQB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AQB is unprofitable, and losses have increased over the past 5 years at a rate of 16.4% per year.

Accelerating Growth: Unable to compare AQB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AQB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (32.6%).


Return on Equity

High ROE: AQB has a negative Return on Equity (-7.53%), as it is currently unprofitable.


Financial Health

How is AquaBounty Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: AQB's short term assets ($213.5M) exceed its short term liabilities ($2.0M).

Long Term Liabilities: AQB's short term assets ($213.5M) exceed its long term liabilities ($8.9M).


Debt to Equity History and Analysis

Debt Level: AQB's debt to equity ratio (3.9%) is considered satisfactory.

Reducing Debt: AQB had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AQB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: AQB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.2% each year


Dividend

What is AquaBounty Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AQB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AQB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AQB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AQB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AQB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Sylvia Wulf (63 yo)

2.58yrs

Tenure

US$534,706

Compensation

Ms. Sylvia A. Wulf has been Chief Executive Officer, President and Executive Director of AquaBounty Technologies, Inc. since January 1, 2019. Ms. Wulf served as Senior Vice President and President of the M...


CEO Compensation Analysis

Compensation vs Market: Sylvia's total compensation ($USD534.71K) is below average for companies of similar size in the US market ($USD1.72M).

Compensation vs Earnings: Sylvia's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AQB's management team is considered experienced (2.1 years average tenure).


Board Members

Experienced Board: AQB's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 121.4%.


Top Shareholders

Company Information

AquaBounty Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AquaBounty Technologies, Inc.
  • Ticker: AQB
  • Exchange: NasdaqCM
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$345.879m
  • Shares outstanding: 71.02m
  • Website: https://www.aquabounty.com

Number of Employees


Location

  • AquaBounty Technologies, Inc.
  • 2 Mill and Main Place
  • Suite 395
  • Maynard
  • Massachusetts
  • 1754
  • United States

Listings


Biography

AquaBounty Technologies, Inc., a biotechnology company, focuses on improving productivity in the commercial aquaculture industry in the United States and Canada. It offers AquAdvantage Salmon, a bioenginee...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/03 00:36
End of Day Share Price2021/08/02 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.